Geriatric Assessment to Improve Treatment and Quality of Life in Older Adults with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Chemotherapy and Radiation

What this Trial Is About

The trial investigates how a geriatric assessment GA combined with GA-directed treatment recommendations compares to GA with usual care in reducing chemotherapy and radiation side effects, functional decline, and improving quality of life in older patients with non-small cell lung cancer NSCLC. Older adults with lung cancer face higher risks of treatment toxicity and physical challenges, making treatment decisions complex. This study aims to help physicians make better treatment choices by providing detailed geriatric evaluations and recommendations. Participants are randomly assigned to one of two groups. In the intervention group, patients complete a geriatric assessment and both patients and their doctors receive summaries and treatment suggestions before starting chemotherapy and radiation, at the treatment midpoint, and at the end. The comparison group also completes the assessment, but only information on significant cognitive issues and depression is shared with their care teams, following usual care practices. Blood and stool samples are collected from all participants at screening and during the study. During the trial, participants are monitored with follow-up visits at 4-6 weeks, 10-14 weeks, and 20-26 weeks after starting treatment. Assessments include tracking severe treatment-related toxicities, patient-reported symptoms, physical function tests, medication use, mood, quality of life, treatment completion, and hospital visits. Additional exploratory measures study microbial diversity and blood markers as potential indicators of treatment response and side effects. The total study duration extends up to about six months after treatment begins.

Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy